<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Methadone - Complete Profile</title>
    <link rel="stylesheet" href="/Dyo-s-Dubious-Domain/style.css">
    <script>
        // Set base path for JavaScript files to use
        window.SITE_BASE_PATH = '/Dyo-s-Dubious-Domain/';
    </script>
</head>

<body class="
  
  
  
  ">
    <header class="page-header">
  <div class="container">
    <div class="page-header__content">
      <div class="logo-container">
        <a href="/Dyo-s-Dubious-Domain/" class="site-title">Dyo's Dubious Domain</a>
      </div>
      
      <nav>
        <ul role="list" class="nav-list flex-group">
          <li>
            <a href="/Dyo-s-Dubious-Domain/">Home</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/dyos-domain/">Dyo's Domain</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/about/">About</a>
          </li>
          <li>
            <a href="/Dyo-s-Dubious-Domain/profile/">My Profile</a>
          </li>
         
        </ul>
      </nav>
    </div>
    
    <!-- Search Bar - Now underneath header -->
    <div class="search-container">
      <input type="text" id="search-input" placeholder="Search substances..." class="search-input" />
      <div id="search-results" class="search-results" style="display: none;"></div>
    </div>
  </div>
</header>

    <main>
      
<div class="substance-profile-header">
  <div class="container">
    <nav class="breadcrumb">
      <a href="/dyos-domain/">Dyo's Domain</a> ‚Üí <a href="/dyos-domain/depressants/">Depressants</a> ‚Üí <span>Methadone</span>
    </nav>
    
    <div class="substance-hero">
      <div class="substance-info">
        <h1>üè• Methadone</h1>
        <h2 class="chemical-name">6-(Dimethylamino)-4,4-diphenyl-3-heptanone</h2>
          <!-- Add to Profile Button -->
        <button id="add-to-profile-btn" class="add-to-profile-btn not-in-profile" 
                data-substance="Methadone" 
                data-category="Depressants" 
                data-chemical="6-(Dimethylamino)-4,4-diphenyl-3-heptanone">
          + Add to My Profile
        </button>
        
        <div class="alternative-names">
          <h3>Alternative Names & Forms</h3>
          <div class="names-grid">
            <div class="name-category">
              <h4>Brand Names</h4>
              <span>Dolophine</span> ‚Ä¢ <span>Methadose</span> ‚Ä¢ <span>Diskets</span> ‚Ä¢ <span>Methadone HCl</span>
            </div>
            <div class="name-category">
              <h4>Street Names</h4>
              <span>Done</span> ‚Ä¢ <span>Meth</span> ‚Ä¢ <span>Juice</span> ‚Ä¢ <span>Red Rock</span> ‚Ä¢ <span>Chocolate Chip Cookies</span>
            </div>
            <div class="name-category">
              <h4>Medical Forms</h4>
              <span>Oral Solution</span> ‚Ä¢ <span>Tablets</span> ‚Ä¢ <span>Dispersible Tablets</span> ‚Ä¢ <span>Injectable</span>
            </div>
            <div class="name-category">
              <h4>Clinical Context</h4>
              <span>MMT (Methadone Maintenance Treatment)</span> ‚Ä¢ <span>ORT (Opioid Replacement Therapy)</span> ‚Ä¢ <span>OST (Opioid Substitution Therapy)</span>
            </div>
          </div>
        </div>
        
        <div class="substance-meta-large">
          <span class="category medical-opioid">Medical Opioid</span>
          <span class="legal-status schedule-2">Schedule II</span>
          <span class="duration extremely-long">24-36 hours</span>
        </div>
      </div>
      
      <div class="substance-visual">
        <div class="substance-image">
          <img src="/assets/substances/methadone.jpg" alt="Methadone tablets, liquid doses and clinic setting" class="substance-photo">
        </div>
        <div class="molecule-structure">
          <div class="structure-placeholder">
            <p>üß¨ C‚ÇÇ‚ÇÅH‚ÇÇ‚ÇáNO</p>
            <p>MW: 309.45 g/mol</p>
            <p>üíä Medical Standard</p>
          </div>
        </div>
      </div>
    </div>
  </div>
</div>

<div class="container">
  
  <div class="profile-grid">
    
    <div class="profile-section identification">
      <h3>üîç Physical Identification</h3>
      <div class="identification-info">
        <div class="pharmaceutical-forms">
          <h4>Pharmaceutical Preparations</h4>
          <div class="form-details">
            <div class="form-type">
              <h5>üíß Oral Solution (Clinic Standard)</h5>
              <ul>
                <li><strong>Appearance:</strong> Clear to pale yellow liquid</li>
                <li><strong>Concentration:</strong> Typically 1mg/mL or 10mg/mL</li>
                <li><strong>Flavoring:</strong> Often cherry, orange, or unflavored</li>
                <li><strong>Dispensing:</strong> Measured doses at licensed clinics</li>
              </ul>
            </div>
            <div class="form-type">
              <h5>üíä Tablets (10mg standard)</h5>
              <ul>
                <li><strong>Appearance:</strong> White, round, scored tablets</li>
                <li><strong>Markings:</strong> "DOLOPHINE" or strength markings</li>
                <li><strong>Availability:</strong> 5mg, 10mg, 40mg strengths</li>
                <li><strong>Dispensing:</strong> Strict prescription control</li>
              </ul>
            </div>
            <div class="form-type">
              <h5>üß™ Dispersible Tablets (Methadose)</h5>
              <ul>
                <li><strong>Appearance:</strong> Orange or green colored tablets</li>
                <li><strong>Function:</strong> Dissolve in water/juice for dosing</li>
                <li><strong>Strengths:</strong> 40mg tablets most common</li>
                <li><strong>Tamper resistance:</strong> Designed to prevent injection</li>
              </ul>
            </div>
          </div>
        </div>
        
        <div class="street-diversion">
          <h4>‚ö†Ô∏è Diverted/Street Forms</h4>
          <ul>
            <li><strong>Clinic bottles:</strong> Amber plastic bottles with patient labels</li>
            <li><strong>Wafers/cookies:</strong> Methadone mixed into edible forms</li>
            <li><strong>Powder:</strong> Crushed tablets or pharmacy-grade powder</li>
            <li><strong>Liquid concentrates:</strong> High-concentration clinic solutions</li>
          </ul>
          <p class="diversion-warning"><strong>üö® Diversion Warning:</strong> Street methadone is extremely dangerous due to variable potency and lack of medical supervision. Overdose risk is extreme.</p>
        </div>

        <div class="medical-context">
          <h4>üè• Medical Administration Context</h4>
          <div class="administration-settings">
            <div class="setting">
              <h5>Methadone Maintenance Clinics</h5>
              <p>Specialized facilities providing daily observed dosing for opioid addiction treatment</p>
            </div>
            <div class="setting">
              <h5>Hospital/Pain Management</h5>
              <p>Inpatient and outpatient chronic pain treatment under physician supervision</p>
            </div>
            <div class="setting">
              <h5>Take-Home Programs</h5>
              <p>Earned privilege allowing stable patients to take doses home (strict regulations)</p>
            </div>
          </div>
        </div>
      </div>
    </div>
    
    <div class="profile-section dosage">
      <h3>üíä Dosage Guidelines</h3>
      
      <div class="medical-dosing">
        <h4>üè• Medical/Therapeutic Dosing</h4>
        <div class="dosage-chart medical">
          <div class="dose-range medical-start">
            <span class="range-label">Initial Treatment</span>
            <span class="dose-amount">20-30mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range medical-maintenance">
            <span class="range-label">Maintenance</span>
            <span class="dose-amount">60-120mg</span>
            <div class="dose-bar"></div>
          </div>
          <div class="dose-range medical-high">
            <span class="range-label">High-Dose Maintenance</span>
            <span class="dose-amount">120-200mg+</span>
            <div class="dose-bar"></div>
          </div>
        </div>
      </div>

      <div class="naive-user-warning">
        <h4>üö® Opioid-Naive User Dangers</h4>
        <div class="danger-levels">
          <div class="danger-level fatal">
            <span class="danger-label">FATAL RISK</span>
            <span class="dose-amount">10-20mg</span>
            <p>Can cause fatal respiratory depression in non-tolerant users</p>
          </div>
          <div class="danger-level extreme">
            <span class="danger-label">EXTREME DANGER</span>
            <span class="dose-amount">5-10mg</span>
            <p>Severe respiratory depression, requires immediate medical attention</p>
          </div>
          <div class="danger-level high">
            <span class="danger-label">HIGH RISK</span>
            <span class="dose-amount">2.5-5mg</span>
            <p>Significant effects in opioid-naive users, still dangerous</p>
          </div>
        </div>
      </div>
      
      <div class="dosage-details">
        <h4>Critical Dosing Considerations</h4>
        <ul>
          <li><strong>Tolerance requirement:</strong> Safe doses require significant opioid tolerance</li>
          <li><strong>Accumulation risk:</strong> 24-36 hour half-life causes dose stacking</li>
          <li><strong>Individual variation:</strong> CYP450 metabolism varies dramatically between people</li>
          <li><strong>Slow onset:</strong> Peak effects 2-4 hours, full effects up to 5 days</li>
          <li><strong>Medical supervision:</strong> Dosing should only occur under medical supervision</li>
          <li><strong>Withdrawal prevention:</strong> Prevents opioid withdrawal for 24+ hours</li>
        </ul>
      </div>
      
      <div class="medical-protocol">
        <h4>üè• Medical Induction Protocol</h4>
        <div class="induction-timeline">
          <div class="timeline-item">
            <span class="time">Day 1</span>
            <span class="protocol">Initial assessment, 20-30mg maximum starting dose</span>
          </div>
          <div class="timeline-item">
            <span class="time">Day 2-3</span>
            <span class="protocol">Assess withdrawal suppression, adjust by 5-10mg increments</span>
          </div>
          <div class="timeline-item">
            <span class="time">Week 1-2</span>
            <span class="protocol">Gradual increases to stabilization dose (typically 60-120mg)</span>
          </div>
          <div class="timeline-item">
            <span class="time">Ongoing</span>
            <span class="protocol">Maintenance dosing with regular medical monitoring</span>
          </div>
        </div>
      </div>
      
      <p class="dosage-note"><strong>‚ö†Ô∏è MEDICAL SUPERVISION REQUIRED:</strong> Methadone dosing outside medical supervision is extremely dangerous and potentially fatal. The therapeutic window between effective and lethal doses is narrow.</p>
    </div>

    <div class="profile-section effects">
      <h3>‚ú® Effects Profile</h3>
      
      <div class="effects-timeline">
        <h4>Timeline (Medical Dosing)</h4>
        <div class="timeline-item">
          <span class="time">T+0:30-2:00</span>
          <span class="effect">Onset - gradual euphoria, pain relief (naive users)</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+2:00-6:00</span>
          <span class="effect">Peak - maximum analgesic/euphoric effects</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+6:00-24:00</span>
          <span class="effect">Plateau - sustained opioid effects, withdrawal blockade</span>
        </div>
        <div class="timeline-item">
          <span class="time">T+24:00-36:00</span>
          <span class="effect">Gradual decline - effects diminish, next dose needed</span>
        </div>
      </div>

      <div class="tolerance-effects">
        <h4>Effects by Tolerance Level</h4>
        <div class="tolerance-categories">
          <div class="tolerance-category naive">
            <h5>‚ùå Opioid-Naive Users</h5>
            <ul>
              <li>Intense euphoria (dangerous - indicates overdose risk)</li>
              <li>Severe respiratory depression</li>
              <li>Extreme sedation and nodding</li>
              <li>Nausea and vomiting</li>
              <li>Risk of fatal overdose</li>
            </ul>
          </div>
          
          <div class="tolerance-category tolerant">
            <h5>‚úÖ Opioid-Tolerant Users (Medical Context)</h5>
            <ul>
              <li>Withdrawal prevention and relief</li>
              <li>Sustained pain relief (if applicable)</li>
              <li>Reduced cravings for other opioids</li>
              <li>Mood stabilization</li>
              <li>Functional improvement</li>
              <li>Minimal euphoria (therapeutic goal)</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="therapeutic-goals">
        <h4>üéØ Therapeutic Treatment Goals</h4>
        <ul>
          <li><strong>Withdrawal elimination:</strong> Complete suppression of opioid withdrawal symptoms</li>
          <li><strong>Craving reduction:</strong> Blockade of euphoric effects from other opioids</li>
          <li><strong>Functional restoration:</strong> Return to normal daily activities and responsibilities</li>
          <li><strong>Harm reduction:</strong> Elimination of injection drug use and associated risks</li>
          <li><strong>Stabilization:</strong> Consistent daily dosing without fluctuations</li>
          <li><strong>Quality of life:</strong> Improved physical and mental health outcomes</li>
        </ul>
      </div>

      <div class="side-effects">
        <h4>Common Side Effects</h4>
        <div class="side-effect-categories">
          <div class="side-effect-category common">
            <h5>Common (Tolerable)</h5>
            <ul>
              <li>Constipation (almost universal)</li>
              <li>Sweating and hot flashes</li>
              <li>Sleep disturbances</li>
              <li>Decreased libido</li>
              <li>Weight gain</li>
            </ul>
          </div>
          
          <div class="side-effect-category serious">
            <h5>Serious (Medical Attention)</h5>
            <ul>
              <li>Respiratory depression</li>
              <li>QT interval prolongation (cardiac)</li>
              <li>Severe sedation</li>
              <li>Hormonal disruption</li>
              <li>Cognitive impairment</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section pharmacology">
      <h3>üß† Pharmacology & Neuroscience</h3>
      <div class="pharma-details">
        <h4>Primary Mechanism of Action</h4>
        <p>Methadone is a full agonist at the Œº-opioid receptor (MOR) with additional activity at delta-opioid receptors and NMDA receptors. Its long half-life and high oral bioavailability make it ideal for once-daily maintenance therapy. Unlike short-acting opioids, methadone provides sustained receptor occupancy without significant fluctuation.</p>
        
        <h4>Detailed Receptor Pharmacology</h4>
        <div class="receptor-table">
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œº-Opioid Receptor (MOR)</strong></span>
            <span class="affinity">High affinity full agonist</span>
            <span class="function">Primary analgesic, euphoric, and respiratory depressant effects</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ¥-Opioid Receptor (DOR)</strong></span>
            <span class="affinity">Moderate affinity agonist</span>
            <span class="function">Additional analgesic effects, mood modulation</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>NMDA Receptor</strong></span>
            <span class="affinity">Non-competitive antagonist</span>
            <span class="function">Anti-hyperalgesic effects, tolerance reduction</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Œ±3Œ≤4 Nicotinic Receptor</strong></span>
            <span class="affinity">Antagonist activity</span>
            <span class="function">May contribute to unique therapeutic profile</span>
          </div>
          <div class="receptor-row">
            <span class="receptor-name"><strong>Potassium Channels (hERG)</strong></span>
            <span class="affinity">Blocking activity</span>
            <span class="function">QT prolongation risk - cardiac toxicity concern</span>
          </div>
        </div>

        <h4>Pharmacokinetics & Metabolism</h4>
        <div class="metabolism-details">
          <p><strong>Absorption:</strong> Well absorbed orally (80-95% bioavailability)</p>
          <p><strong>Distribution:</strong> Highly protein bound (85-90%), large volume of distribution</p>
          <p><strong>Metabolism:</strong> Hepatic via CYP3A4, CYP2B6, CYP2C19, CYP2D6</p>
          <p><strong>Half-life:</strong> 24-36 hours (highly variable, 8-72 hour range)</p>
          <p><strong>Peak plasma:</strong> 2-4 hours oral administration</p>
          <p><strong>Excretion:</strong> Primarily renal as metabolites</p>
          <p><strong>Steady state:</strong> Achieved after 5-7 days of consistent dosing</p>
        </div>

        <h4>Unique Pharmacological Properties</h4>
        <div class="unique-properties">
          <p><strong>Racemic mixture:</strong> Contains both R- and S-enantiomers with different properties</p>
          <p><strong>R-methadone:</strong> Primary opioid activity, longer half-life</p>
          <p><strong>S-methadone:</strong> NMDA antagonism, shorter half-life, cardiac effects</p>
          <p><strong>Tissue accumulation:</strong> Stores in liver and other tissues, contributing to long duration</p>
          <p><strong>Auto-induction:</strong> May induce its own metabolism with chronic use</p>
        </div>

        <h4>Drug Interactions - Metabolic</h4>
        <div class="metabolic-interactions">
          <div class="interaction-category inducers">
            <h5>CYP450 Inducers (Decrease Methadone Levels)</h5>
            <ul>
              <li><strong>Rifampin:</strong> Can reduce methadone levels by 50-60%</li>
              <li><strong>Phenytoin:</strong> Significant reduction in methadone effectiveness</li>
              <li><strong>Carbamazepine:</strong> Withdrawal symptoms may emerge</li>
              <li><strong>St. John's Wort:</strong> Herbal inducer causing withdrawal risk</li>
            </ul>
          </div>
          <div class="interaction-category inhibitors">
            <h5>CYP450 Inhibitors (Increase Methadone Levels)</h5>
            <ul>
              <li><strong>Fluconazole:</strong> Can double methadone concentrations</li>
              <li><strong>Ciprofloxacin:</strong> Significant increase in sedation risk</li>
              <li><strong>Grapefruit juice:</strong> CYP3A4 inhibition increasing levels</li>
              <li><strong>Protease inhibitors:</strong> HIV medications affecting metabolism</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section safety">
      <h3>‚ö†Ô∏è Safety & Harm Reduction</h3>
      
      <div class="safety-grid">
        <div class="safety-item critical">
          <h4>üö® Life-Threatening Risks</h4>
          <ul>
            <li><strong>Respiratory depression:</strong> Can be fatal, especially in naive users</li>
            <li><strong>QT prolongation:</strong> Cardiac arrhythmias, sudden death risk</li>
            <li><strong>Overdose accumulation:</strong> Long half-life causes dose stacking</li>
            <li><strong>Benzodiazepine interaction:</strong> Exponentially increases overdose risk</li>
            <li><strong>Withdrawal complexity:</strong> Prolonged, severe withdrawal syndrome</li>
          </ul>
        </div>
        
        <div class="safety-item medical-supervision">
          <h4>üè• Medical Supervision Requirements</h4>
          <ul>
            <li><strong>Cardiac monitoring:</strong> ECG screening for QT prolongation</li>
            <li><strong>Dose titration:</strong> Gradual increases under medical supervision</li>
            <li><strong>Drug interaction screening:</strong> Comprehensive medication review</li>
            <li><strong>Regular monitoring:</strong> Ongoing assessment of effectiveness and side effects</li>
            <li><strong>Take-home privileges:</strong> Earned through demonstrated stability</li>
          </ul>
        </div>
      </div>

      <div class="overdose-recognition">
        <h4>üö® Overdose Recognition & Response</h4>
        <div class="overdose-signs">
          <h5>Critical Signs</h5>
          <ul>
            <li><strong>Respiratory depression:</strong> Slow, shallow, or absent breathing</li>
            <li><strong>Blue lips/fingernails:</strong> Cyanosis indicating oxygen deprivation</li>
            <li><strong>Unconsciousness:</strong> Cannot be roused by loud noises or pain</li>
            <li><strong>Weak pulse:</strong> Slow, irregular, or weak heartbeat</li>
            <li><strong>Cold, clammy skin:</strong> Poor circulation</li>
          </ul>
        </div>
        <div class="overdose-response">
          <h5>Emergency Response</h5>
          <ul>
            <li><strong>Call 911 immediately:</strong> Medical emergency requiring hospital care</li>
            <li><strong>Naloxone (Narcan):</strong> May require multiple doses due to long half-life</li>
            <li><strong>Rescue breathing:</strong> Support breathing if trained</li>
            <li><strong>Recovery position:</strong> Prevent choking on vomit</li>
            <li><strong>Stay until help arrives:</strong> Naloxone may wear off before methadone</li>
          </ul>
        </div>
      </div>

      <div class="contraindications">
        <h4>üö´ Absolute Contraindications</h4>
        <ul>
          <li><strong>Respiratory depression:</strong> Current severe breathing problems</li>
          <li><strong>Severe asthma:</strong> Risk of fatal respiratory complications</li>
          <li><strong>QT prolongation:</strong> Pre-existing cardiac conduction abnormalities</li>
          <li><strong>Opioid naive status:</strong> No significant opioid tolerance</li>
          <li><strong>Concurrent benzodiazepines:</strong> Without careful medical supervision</li>
        </ul>
      </div>
    </div>

    <div class="profile-section interactions">
      <h3>‚öóÔ∏è Drug Interactions</h3>
      
      <div class="interaction-levels">
        <div class="interaction dangerous">
          <h4>üî¥ Potentially Fatal</h4>
          <ul>
            <li><strong>Benzodiazepines:</strong> Exponential increase in overdose risk - most common cause of methadone deaths</li>
            <li><strong>Alcohol:</strong> Severe respiratory depression, loss of consciousness</li>
            <li><strong>Other opioids:</strong> Additive CNS depression, overdose risk</li>
            <li><strong>Gabapentinoids:</strong> Pregabalin/gabapentin increase respiratory depression risk</li>
            <li><strong>Barbiturates:</strong> Profound CNS depression</li>
          </ul>
        </div>
        
        <div class="interaction risky">
          <h4>üü° High Risk</h4>
          <ul>
            <li><strong>Sedatives:</strong> Z-drugs (zolpidem, zopiclone) increase sedation</li>
            <li><strong>Muscle relaxants:</strong> Baclofen, carisoprodol enhance CNS depression</li>
            <li><strong>Antihistamines:</strong> Diphenhydramine, promethazine increase sedation</li>
            <li><strong>Antipsychotics:</strong> Some increase QT prolongation risk</li>
          </ul>
        </div>
        
        <div class="interaction metabolic">
          <h4>üü† Metabolic Interactions</h4>
          <ul>
            <li><strong>CYP450 Inducers:</strong> Rifampin, phenytoin reduce methadone levels</li>
            <li><strong>CYP450 Inhibitors:</strong> Fluconazole, ciprofloxacin increase levels</li>
            <li><strong>HIV medications:</strong> Complex interactions requiring dose adjustments</li>
            <li><strong>Antidepressants:</strong> Some SSRIs inhibit methadone metabolism</li>
          </ul>
        </div>

        <div class="interaction cardiac">
          <h4>üíì Cardiac Risk Interactions</h4>
          <ul>
            <li><strong>QT-prolonging drugs:</strong> Antiarrhythmics, some antibiotics</li>
            <li><strong>Electrolyte-affecting drugs:</strong> Diuretics causing hypokalemia</li>
            <li><strong>Tricyclic antidepressants:</strong> Additional QT prolongation</li>
            <li><strong>Antipsychotics:</strong> Haloperidol, ziprasidone cardiac risks</li>
          </ul>
        </div>
      </div>

      <div class="food-interactions">
        <h4>üçä Food & Supplement Interactions</h4>
        <ul>
          <li><strong>Grapefruit juice:</strong> Increases methadone levels significantly</li>
          <li><strong>St. John's Wort:</strong> Reduces methadone effectiveness</li>
          <li><strong>High-fat meals:</strong> May increase absorption</li>
          <li><strong>Acidic drinks:</strong> May affect oral solution absorption</li>
        </ul>
      </div>
    </div>

    <div class="profile-section legal">
      <h3>‚öñÔ∏è Legal Status & Regulation</h3>
      <div class="legal-info">
        <div class="legal-jurisdictions">
          <div class="jurisdiction">
            <h4>üá∫üá∏ United States</h4>
            <p><strong>Schedule II</strong> - High abuse potential but accepted medical use. Strict prescription controls and DEA registration required.</p>
            <div class="us-regulations">
              <h5>Specific Regulations</h5>
              <ul>
                <li><strong>Methadone clinics:</strong> Must be DEA and SAMHSA certified</li>
                <li><strong>Daily dosing:</strong> Initial treatment requires daily clinic visits</li>
                <li><strong>Take-home privileges:</strong> Earned based on stability and compliance</li>
                <li><strong>Pain management:</strong> Separate regulations for chronic pain treatment</li>
              </ul>
            </div>
          </div>
          <div class="jurisdiction">
            <h4>üá¨üáß United Kingdom</h4>
            <p><strong>Class A</strong> - Controlled drug with strict prescribing regulations. Available through specialized addiction services and pain clinics.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá®üá¶ Canada</h4>
            <p><strong>Schedule I</strong> - Controlled substance available through methadone maintenance programs and specialized prescribers.</p>
          </div>
          <div class="jurisdiction">
            <h4>üá¶üá∫ Australia</h4>
            <p><strong>Schedule 8</strong> - Controlled drug requiring special prescriber authorization and patient monitoring.</p>
          </div>
        </div>
        
        <div class="prescribing-requirements">
          <h4>üë®‚Äç‚öïÔ∏è Prescribing Requirements</h4>
          <div class="requirement-categories">
            <div class="requirement-category">
              <h5>Prescriber Requirements</h5>
              <ul>
                <li>Special DEA registration for addiction treatment</li>
                <li>Training in addiction medicine or pain management</li>
                <li>Ongoing education requirements</li>
                <li>Regular audit and compliance monitoring</li>
              </ul>
            </div>
            <div class="requirement-category">
              <h5>Patient Requirements</h5>
              <ul>
                <li>Documented opioid use disorder (addiction treatment)</li>
                <li>Medical evaluation and assessment</li>
                <li>Informed consent and treatment agreement</li>
                <li>Regular monitoring and compliance testing</li>
              </ul>
            </div>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section history">
      <h3>üìö History & Development</h3>
      
      <div class="history-timeline">
        <div class="history-event">
          <span class="year">1937</span>
          <p>Synthesized by German scientists Max Bockm√ºhl and Gustav Ehrhart at IG Farben</p>
        </div>
        <div class="history-event">
          <span class="year">1947</span>
          <p>Introduced to US market as "Dolophine" for pain management</p>
        </div>
        <div class="history-event">
          <span class="year">1965</span>
          <p>Vincent Dole and Marie Nyswander pioneer methadone maintenance treatment</p>
        </div>
        <div class="history-event">
          <span class="year">1972</span>
          <p>FDA approves methadone for opioid addiction treatment</p>
        </div>
        <div class="history-event">
          <span class="year">1980s</span>
          <p>Expansion of methadone maintenance programs across the US</p>
        </div>
        <div class="history-event">
          <span class="year">2000s</span>
          <p>Increased use for chronic pain management leads to overdose epidemic</p>
        </div>
        <div class="history-event">
          <span class="year">2010s</span>
          <p>Enhanced safety protocols and cardiac monitoring requirements</p>
        </div>
      </div>

      <div class="development-context">
        <h4>Historical Context</h4>
        <p><strong>World War II development:</strong> Originally developed as a synthetic alternative to morphine when opium supplies were threatened during WWII. The name "Dolophine" was chosen for its analgesic properties, contrary to urban legends attributing it to Adolf Hitler.</p>
        
        <p><strong>Addiction treatment revolution:</strong> The work of Vincent Dole and Marie Nyswander in the 1960s revolutionized addiction treatment by demonstrating that methadone maintenance could help heroin addicts return to functional lives.</p>
      </div>

      <div class="cultural-impact">
        <h4>Social Impact</h4>
        <div class="impact-areas">
          <div class="impact-positive">
            <h5>‚úÖ Positive Developments</h5>
            <ul>
              <li>Dramatic reduction in injection drug use and associated diseases</li>
              <li>Decreased criminal activity among treatment participants</li>
              <li>Improved family and social functioning</li>
              <li>Reduced overdose deaths when properly administered</li>
            </ul>
          </div>
          <div class="impact-challenges">
            <h5>‚ö†Ô∏è Ongoing Challenges</h5>
            <ul>
              <li>Stigma surrounding methadone maintenance treatment</li>
              <li>Diversion and illegal distribution concerns</li>
              <li>Geographic barriers to accessing treatment</li>
              <li>Insurance and funding limitations</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section research">
      <h3>üî¨ Current Research & Clinical Applications</h3>
      
      <div class="research-areas">
        <div class="research-item">
          <h4>Treatment Optimization</h4>
          <p>Research into optimal dosing strategies, split-dosing protocols, and personalized medicine approaches based on genetic polymorphisms affecting methadone metabolism.</p>
        </div>
        
        <div class="research-item">
          <h4>Cardiac Safety</h4>
          <p>Ongoing studies examining QT prolongation risk factors, cardiac monitoring protocols, and safer alternatives for high-risk patients.</p>
        </div>
        
        <div class="research-item">
          <h4>Pregnancy & Neonatal</h4>
          <p>Research into methadone use during pregnancy, neonatal abstinence syndrome management, and long-term developmental outcomes.</p>
        </div>
        
        <div class="research-item">
          <h4>Alternative Formulations</h4>
          <p>Development of abuse-deterrent formulations and novel delivery systems to improve safety and patient outcomes.</p>
        </div>

        <div class="research-item">
          <h4>Pain Management Applications</h4>
          <p>Studies examining methadone's role in chronic pain management, rotation from other opioids, and neuropathic pain treatment.</p>
        </div>
      </div>

      <div class="clinical-guidelines">
        <h4>üìã Current Clinical Guidelines</h4>
        <div class="guideline-categories">
          <div class="guideline-category">
            <h5>Treatment Initiation</h5>
            <ul>
              <li>Comprehensive medical and psychiatric evaluation</li>
              <li>Assessment of opioid tolerance and withdrawal severity</li>
              <li>Cardiac screening including ECG</li>
              <li>Conservative initial dosing (20-30mg maximum)</li>
            </ul>
          </div>
          <div class="guideline-category">
            <h5>Maintenance Phase</h5>
            <ul>
              <li>Regular dose adjustment to eliminate withdrawal and craving</li>
              <li>Ongoing cardiac monitoring for QT prolongation</li>
              <li>Comprehensive substance abuse counseling</li>
              <li>Medical management of side effects</li>
            </ul>
          </div>
          <div class="guideline-category">
            <h5>Take-Home Privileges</h5>
            <ul>
              <li>Demonstration of treatment stability</li>
              <li>Negative drug screens</li>
              <li>Regular counseling participation</li>
              <li>Safe storage requirements</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

    <div class="profile-section treatment-context">
      <h3>üè• Treatment Context & Accessibility</h3>
      
      <div class="treatment-settings">
        <div class="setting-type">
          <h4>üè¢ Methadone Maintenance Clinics</h4>
          <div class="clinic-details">
            <h5>Services Provided</h5>
            <ul>
              <li>Daily observed dosing</li>
              <li>Individual and group counseling</li>
              <li>Medical monitoring and management</li>
              <li>Social services coordination</li>
              <li>Take-home dose programs</li>
            </ul>
            <h5>Accessibility Barriers</h5>
            <ul>
              <li>Geographic limitations - not available in all areas</li>
              <li>Transportation requirements for daily visits</li>
              <li>Employment conflicts with clinic hours</li>
              <li>Insurance coverage limitations</li>
              <li>Social stigma and discrimination</li>
            </ul>
          </div>
        </div>

        <div class="setting-type">
          <h4>üè• Medical Pain Management</h4>
          <div class="pain-management-details">
            <h5>Indications</h5>
            <ul>
              <li>Chronic pain unresponsive to other opioids</li>
              <li>Opioid rotation for tolerance or side effects</li>
              <li>Neuropathic pain conditions</li>
              <li>Cancer pain management</li>
            </ul>
            <h5>Monitoring Requirements</h5>
            <ul>
              <li>Regular physician visits</li>
              <li>Cardiac monitoring (ECG)</li>
              <li>Drug screening when indicated</li>
              <li>Assessment of pain and function</li>
            </ul>
          </div>
        </div>
      </div>

      <div class="treatment-outcomes">
        <h4>üìä Treatment Effectiveness</h4>
        <div class="outcome-metrics">
          <div class="outcome-category">
            <h5>Addiction Treatment Outcomes</h5>
            <ul>
              <li><strong>Retention rates:</strong> 60-80% at 1 year with adequate dosing</li>
              <li><strong>Illicit opioid use:</strong> 70-90% reduction in street drug use</li>
              <li><strong>Criminal activity:</strong> Significant reduction in drug-related crimes</li>
              <li><strong>Employment:</strong> Improved job stability and income</li>
              <li><strong>Health outcomes:</strong> Reduced HIV/HCV transmission, improved overall health</li>
            </ul>
          </div>
          <div class="outcome-category">
            <h5>Pain Management Outcomes</h5>
            <ul>
              <li><strong>Pain relief:</strong> Effective for chronic and neuropathic pain</li>
              <li><strong>Functional improvement:</strong> Enhanced quality of life measures</li>
              <li><strong>Opioid rotation:</strong> Successful alternative when other opioids fail</li>
              <li><strong>Side effect management:</strong> Different side effect profile may benefit some patients</li>
            </ul>
          </div>
        </div>
      </div>
    </div>

  </div>

  <div class="substance-resources">
    <h3>üìñ Additional Resources</h3>
    <div class="resources-grid">
      <div class="resource-item">
        <h4>Treatment Locators</h4>
        <ul>
          <li><a href="https://www.samhsa.gov/find-treatment">SAMHSA Treatment Locator</a> - Find methadone clinics</li>
          <li><a href="https://www.naabt.org/">NAABT</a> - National Alliance for Addiction Treatment</li>
          <li><a href="https://www.methadone.org/">Methadone.org</a> - Treatment information and advocacy</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Medical Resources</h4>
        <ul>
          <li><a href="https://www.asam.org/">ASAM</a> - American Society of Addiction Medicine</li>
          <li><a href="https://www.cdc.gov/opioids/">CDC Opioid Resources</a> - Clinical guidelines and information</li>
          <li><a href="https://www.ncbi.nlm.nih.gov/books/NBK143185/">SAMHSA Guidelines</a> - Clinical guidelines for methadone use</li>
        </ul>
      </div>
      
      <div class="resource-item">
        <h4>Support & Advocacy</h4>
        <ul>
          <li><a href="https://www.harmreduction.org/">Harm Reduction Coalition</a> - Advocacy and education</li>
          <li><a href="https://www.drugpolicy.org/">Drug Policy Alliance</a> - Policy reform and education</li>
          <li><a href="https://www.reddit.com/r/Methadone/">/r/Methadone</a> - Peer support community</li>
        </ul>
      </div>
    </div>
  </div>

</div>
    </main>
     <div class="footer-divider"></div>
<footer class="site-footer">
  
</footer>




<footer class="site-footer">
  
  </svg>
    <img src="/assets/logo.svg" alt="My Logo" class="logo">
     <p>¬© 2025 Uwaniumnya. Highly Illegal.</p>
  </footer>

  

    <!-- Search Scripts -->
    <script src="/Dyo-s-Dubious-Domain/js/lunr.min.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/search.js"></script>
    <script src="/Dyo-s-Dubious-Domain/assets/js/substance-integration.js"></script>
    
    <!-- Only load profile.js on profile page -->
    
</body>
</html>